stocks logo

PTGX

Protagonist Therapeutics Inc
$
53.750
+2.68(5.248%)1D
  • Overview
  • Forecast
  • Valuation
  • Earnings
Line
Line
|
Candle
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
53.800
Open
51.050
VWAP
52.49
Vol
866.49K
Mkt Cap
3.34B
Low
50.580
Amount
45.48M
EV/EBITDA(TTM)
101.42
Total Shares
58.65M
EV
2.61B
EV/OCF(TTM)
65.92
P/S(TTM)
15.55
Protagonist Therapeutics, Inc. is a biopharmaceutical company focused on peptide therapeutics. The Company’s clinical programs fall into two categories of diseases: hematology and blood disorders, and inflammatory and immunomodulatory diseases. Its two peptides derived from its proprietary discovery technology platform, rusfertide and icotrokinra, are in advanced Phase III clinical development. Its rusfertide (PTG-300) is an injectable hepcidin mimetic in development for the potential treatment of polycythemia vera (PV) and other blood disorders. Icotrokinra, an orally delivered IL-23R specific antagonist for the potential treatment of psoriasis, psoriatic arthritis (PsA), ulcerative colitis and inflammatory bowel disease (IBD) indications. The Company also has a pre-clinical stage oral drug discovery program addressing clinically and commercially validated targets, including the IL-17 oral peptide antagonist PN-881, an oral hepcidin program, and an oral obesity program.
Show More

Market Estimates

Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q3
FY2025Q4
FY2026Q1
6.56M
+40.38%
--
--
45.32M
-73.44%
--
--
60.19M
+112.53%
--
--
Estimates Revision
The market is revising Downward the revenue expectations for Protagonist Therapeutics, Inc. (PTGX) for FY2025, with the revenue forecasts being adjusted by -0.74% over the past three months. During the same period, the stock price has changed by 18.73%.
Revenue Estimates for FY2025
Revise Downward
down Image
-0.74%
In Past 3 Month
Stock Price
Go Up
up Image
+18.73%
In Past 3 Month
10 Analyst Rating
up Image
28.78% Upside
Wall Street analysts forecast PTGX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PTGX is 69.22 USD with a low forecast of 54.00 USD and a high forecast of 82.00  USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
9 Buy
1 Hold
0 Sell
Strong Buy
up Image
28.78% Upside
Current: 53.750
sliders
Low
54.00
Averages
69.22
High
82.00
Citizens JMP
Outperform
maintain
$67 -> $69
2025-08-07
New
Reason
Citizens JMP raised the firm's price target on Protagonist Therapeutics to $69 from $67 and keeps an Outperform rating on the shares following the Q2 report. The company remains on track to submit its application for rusfertide in polycythemia vera next quarter, with two new candidates nearing clinical testing, the analyst tells investors in a research note.
Citi
Geoff Meacham
initiated
$72
2025-06-18
Reason
Citi analyst Geoff Meacham initiated coverage of Protagonist Therapeutics with a Buy rating and $72 price target. The firm cites the potential of rusfertide in polycythemia vera and oral IL-23 in multi-billion inflammation indications for the Buy rating. Citi acknowledges the share outperformance over past three months, but believes rusfertide's "impressive efficacy" as demonstrated in Phase 3, including improvement in quality of life scores, suggests the drug has "strong potential" in polycythemia vera patients as despite therapeutic advancement there still remains unmet need.
HC Wainwright & Co.
Douglas Tsao
Strong Buy
Reiterates
$80
2025-04-10
Reason
Wedbush
Yun Zhong
Buy
Reiterates
$70
2025-03-28
Reason
HC Wainwright & Co.
Douglas Tsao
Strong Buy
Maintains
$54 → $80
2025-03-11
Reason
BMO Capital
Etzer Darout
Buy
Reiterates
$62 → $72
2025-03-11
Reason

Valuation Metrics

The current forward P/E ratio for Protagonist Therapeutics Inc (PTGX.O) is -35.53, compared to its 5-year average forward P/E of -19.24. For a more detailed relative valuation and DCF analysis to assess Protagonist Therapeutics Inc 's fair value, click here.

Forward PE

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-19.24
Current PE
-35.53
Overvalued PE
20.86
Undervalued PE
-59.35

Forward EV/EBITDA

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
2.65
Current EV/EBITDA
-49.34
Overvalued EV/EBITDA
45.44
Undervalued EV/EBITDA
-40.15

Forward PS

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Fair
5Y Average PS
41.15
Current PS
30.42
Overvalued PS
68.93
Undervalued PS
13.37

Financials

Annual
Quarterly
FY2025Q2
YoY :
+33.09%
5.55M
Total Revenue
FY2025Q2
YoY :
+8.37%
-42.04M
Operating Profit
FY2025Q2
YoY :
+13.57%
-34.77M
Net Income after Tax
FY2025Q2
YoY :
+10.00%
-0.55
EPS - Diluted
FY2025Q2
YoY :
-111.02%
-29.59M
Free Cash Flow
FY2025Q2
YoY :
0.00%
100.00
Gross Profit Margin - %
FY2025Q2
YoY :
-75.48%
17.74
FCF Margin - %
FY2025Q2
YoY :
-14.67%
-626.96
Net Margin - %
FY2025Q2
N/A
ROIC

Trading Trends

Insider
Insiders areSelling! The selling amount has increased 206.61% over the last month.
Sold
0-3
Months
4.6M
USD
6
3-6
Months
3.5M
USD
4
6-9
Months
204.6K
USD
1
0-12
Months
12.8M
USD
9
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
286.4K
Volume
2
6-9
Months
168.5K
Volume
2
0-12
Months
0.0
Volume
0
Bought
0-3
1
250.0K
Volume
Months
3-6
2
895.9K
Volume
Months
6-9
7
1.9M
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months

PTGX News & Events

Events Timeline

2025-07-21 (ET)
2025-07-21
08:25:57
Protagonist Therapeutics, Johnson & Johnson submit icotrokinra NDA to FDA
select
2025-07-21
08:22:05
Protagonist announces NDA submission by Johnson & Johnson for icotrokinra
select
2025-06-01 (ET)
2025-06-01
16:01:08
Protagonist, Takeda announces Phase 3 VERIFY study met primary endpoint
select
Sign Up For More Events

News

9.5
08-07NASDAQ.COM
Protagonist (PTGX) Q2 Revenue Falls 26%
3.0
07-28NASDAQ.COM
XSMO's Underlying Holdings Could Mean 15% Gain Potential
5.0
07-24Yahoo Finance
Protagonist Therapeutics Insider Sold Shares Worth $2,880,044, According to a Recent SEC Filing
Sign Up For More News

FAQ

arrow icon

What is Protagonist Therapeutics Inc (PTGX) stock price today?

The current price of PTGX is 53.75 USD — it has increased 5.25 % in the last trading day.

arrow icon

What is Protagonist Therapeutics Inc (PTGX)'s business?

arrow icon

What is the price predicton of PTGX Stock?

arrow icon

What is Protagonist Therapeutics Inc (PTGX)'s revenue for the last quarter?

arrow icon

What is Protagonist Therapeutics Inc (PTGX)'s earnings per share (EPS) for the last quarter?

arrow icon

What changes have occurred in the market's expectations for Protagonist Therapeutics Inc (PTGX)'s fundamentals?

arrow icon

How many employees does Protagonist Therapeutics Inc (PTGX). have?

arrow icon

What is Protagonist Therapeutics Inc (PTGX) market cap?